Anthrax immune globulin - Emergent BioSolutions

Drug Profile

Anthrax immune globulin - Emergent BioSolutions

Alternative Names: AIG; Anthrax IG Therapeutic - Emergent BioSolutions; Anthrax Immune Globulin Intravenous (AIGIV) - Emergent BioSolutions; Anthrivig

Latest Information Update: 18 Sep 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Emergent BioSolutions
  • Class Immunoglobulins; Polyclonal antibodies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Anthrax
  • New Molecular Entity No

Highest Development Phases

  • No development reported Anthrax

Most Recent Events

  • 18 Sep 2015 No recent reports on development identified - Phase-III for Anthrax (In volunteers) in USA (IV)
  • 08 Mar 2013 Anthrax immune globulin - Emergent BioSolutions receives Orphan Drug status for Anthrax in European Union
  • 08 Mar 2013 Anthrax immune globulin - Emergent BioSolutions receives Orphan Drug status for Anthrax in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top